Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Sarcoma, Alveolar Soft Part 1Papillomavirus Infections 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Colonic Neoplasms 1Carcinoma in Situ 1Burkitt Lymphoma 1

Interventions

Fluorouracil 70Leucovorin 66Oxaliplatin 50Irinotecan 32Cetuximab 23Bevacizumab 20Capecitabine 16Chemotherapy, Adjuvant 15Folfox protocol 13sargramostim 7Neoadjuvant Therapy 7Erlotinib Hydrochloride 7aldesleukin 5Trastuzumab 5Melphalan 5Magnetic Resonance Spectroscopy 5Gene Expression Profiling 5Floxuridine 5Biopsy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5dehydroftorafur 4Specimen Handling 4Polymerase Chain Reaction 4Interferon-alpha 4Immunoglobulin G 4Gemcitabine 4Gefitinib 4Disulfides 4Cyclophosphamide 4fludarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Colonic Neoplasms × Prochlorperazine × Clear all
NCT01851369 2024-05-08

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
93 enrolled 27 charts
GastrointestinalLymphoid

Colonic Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡